Background MRI-US fusion prostate biopsies are becoming a common procedure to diagnose prostate cancer. There is a paucity of information regarding the learning curve for fusion biopsies. We aim to study the amount of experience needed to be both accurate and time-efficient in this procedure. Methods We prospectively collected data on all MRI-US fusion biopsies performed from April 2014 to August 2017. We used two parameters to define the learning curve. Process Measurement (efficiency) was measured by time from the beginning of anesthesia to end of procedure. Outcome Measurement (accuracy) was measured by cancer detection rate for PI-RAD 3 lesions. The end of the learning curve was defined graphically and mathematically. We performed a separate analysis for transrectal and transperineal biopsies. Results We completed 779 fusion biopsies (523 transrectal, 256 transperineal). Patients median age was 66 years (IQR 61-70) and median PSA 6.95 ng/ml (IQR 4.2-10.6). Prostate cancer was diagnosed in 385 (49%). Process Measurement-Procedure time decreased from 45 min in the first transrectal fusion biopsy to 15 min after 109 biopsies and remained stable (p < 0.0001). Time decreased from 55 min in the first transperineal biopsy to 18 min after 124 biopsies (p < 0.0001). Outcome Measurement-In transrectal fusion-biopsies detection rate for PI-RADS 3 lesions increased from 35 to 50% after 104 biopsies. In transperineal fusion-biopsies, detection rate increased from 40 to 55% after 119 cases for PI-RADS 3 lesions. Conclusions We measured the learning curve of fusion biopsies graphically and mathematically. We demonstrated that proficiency occurs after 110 transrectal and 125 transperineal fusion-biopsies.
Introduction
For many years prostate cancer has been detected by randomly sampling the entire organ. The introduction of multiparametric magnetic resonance imaging (MP-MRI) led to the development of image-based prostate biopsies. This has resulted in increased detection of high-risk prostate cancer and decreased detection clinically insignificant cancers [1] [2] [3] [4] .
The PROMIS trial was the first study to provide level 1 evidence for the diagnostic performance of MP-MRI validated against transperineal template biopsy in biopsy-naive men [5] . The PRECISION trial demonstrated in a randomized fashion that MRI-targeted biopsies are superior to systematic biopsies for patients with a raised PSA level who have not undergone biopsy. Clinically significant prostate cancer (Gleason score 3 + 4 or higher) detection was higher in the MRI group in comparison to standard biopsy (38% vs. 26%) as well as fewer diagnoses with clinically insignificant cancer (9% vs. 22%) [6] .
Thus, image-guided prostate biopsy using MRI-US fusion software is becoming standard of care in many urological institutes. This novel approach requires a multidisciplinary cooperative effort beginning with the MRI technicians, interpreting radiologists, image segmentation, and the urologist. At any point in this process the human factor may affect the accuracy of biopsy targeting. The authors of the PRECISION trial have declared observed differences among different centers in the detection of clinically significant cancers: underscoring the importance of expertise needed for targeted biopsies [6] .
Mastering new technologies is an important aspect of any medical field. Despite this, studying the amount of expertise needed to become proficient rarely occurs. In this study, we sought to evaluate the learning curve of MRI-US fusion biopsies.
Patients and methods

Patient population
The study consisted of 779 consecutive men undergoing MRI-based targeted prostate biopsy by a single urologic oncologist (D.M.) from April 2014 to August 2017. Data were prospectively collected from the first case. Inclusion criteria for this study were patients who underwent a MP-MRI that demonstrated at least 1 suspicious lesion in the prostate suggestive of prostate cancer, and were scored according to the prostate imaging reporting and data system (PI-RADS score ≥ 3). Written informed consent was obtained from all participants. The study was performed in two institutions: Rabin medical center and Ramat Aviv medical center. The study protocol was approved by the ethics review board.
Imaging
All patients underwent MP-MRI on a 1.5-T MRI with a pelvic-array coil or a 3.0-T MRI without a pelvic-array coil. All patients had at least three sequences-triplanar T2weighted, dynamic contrast-enhanced, and diffusionweighted imaging. Region of interest (ROI) identified on MRI was scored according to PI-RADS criteria. The first 310 cases were evaluated by the PI-RADS v1 and since February 2016 by the PI-RADS v2 [7, 8] . The MP-MRI images were interpreted by numerous radiologists (>10) with diverse experience in reading prostate MP-MRI at the study entry point. A single physician (D.M.) marked the ROIs in the fusion biopsies according to the radiologist MRI interpretation. For men with multiple ROIs with different PI-RADS lesions, the highest PI-RADS was recorded as representing the overall PI-RADS for that patient.
Biopsy protocol
Patients with lesions classified at least PI-RADS 3 or more underwent MRI-targeted biopsy followed by a systematic biopsy in the same session.
All patients undergoing prostate biopsy were given an antibiotic prophylaxis and a cleansing fleet enema. Biopsies were performed either transrectaly or transperinealy at the surgeons discretion.
Transrectal MRI-US fusion biopsy
Transrectal ultrasound (TRUS) biopsies were done in the outpatient clinic under local periprostatic 10cc of 1% lidocaine in the left lateral decubitus position. Using the Navigo™ system (UC-Care, Israel), the targeted biopsy was performed with the previously identified MP-MRI lesions superimposed using the T2-weighted sequence on the realtime TRUS images. Each lesion was sampled both in the axial and sagittal planes by a side-fire TRUS probe (BK flex 500, Germany). From Four to six samples were taken from each suspicious lesion. Systematic biopsy was typically 12 cores collected in the extended-sextant template biopsy from the medial and lateral aspects of the apical, mid, and base of the prostate on the left and right side. These were performed in areas not sampled by targeted biopsies.
Transperineal MRI-US fusion biopsy
Transperineal fusion biopsies were performed at two institutions (Rabin medical center and Ramat Aviv medical center). Transperineal biopsies at Ramat Aviv were performed using the Biojet rigid image-fusion platform (D&K Technologies GmbH, Barum, Germany) and at Rabin medical center using the Navigo™ system (UC-care, Israel). Transperineal biopsies were done under general anesthesia with the patient in the extended lithotomy position using a 5-mm brachytherapy grid. Four to six samples were taken from each suspicious lesion. Systematic biopsy was typically 12 cores collected in the extended-sextant template biopsy from the medial and lateral aspects of the apical, mid, and base of the prostate on the left and right side. These were performed in areas not sampled by targeted biopsies.
For both the transrectal and transperineal approach prostate cancer detection rates are reported for the fusion biopsy solely.
Definition of variables
For each patient, the urologist experience was coded at the total number of MP-MRI biopsies performed by the urologist before the patient's procedure.
We collected clinical data including age at biopsy, PSA level, prostate volume (measured by MRI), PSA density, previous biopsies, family history of prostate cancer and history of previous prostate cancer diagnosis, mode of biopsy (transrectal vs. transperineal), and fusion software (Navigo vs. BioJet).
Outcome definition
Two parameters were used to define the learning curve.
(1) Process measurement (efficiency)-measured by time of procedure. For transrectal biopsy time we measured time from the beginning of transrectal ultrasound scanning until the last systematic biopsy. For transperineal biopsy we measured time from the beginning of anesthesia until the completion of the procedure with injection of local anesthesia. Data of the procedure time were obtained from the outpatient and operating room logbooks.
(2) Outcome measurement (accuracy)-was defined as the rate of prostate cancer diagnosis and significant prostate cancer diagnosis (International Society of Urological Pathology grading of prostate cance risk group ≥2) [9] and stratified by PI-RADS score (3) (4) (5) and biopsy approach (transrectal vs. transperineal).
Statistical analysis
Process measurement (efficiency)
We used both graphical and mathematical analysis to determine the number of fusion biopsies that are needed to become efficient. Graphically we plotted time of procedure against surgeon experience and defined reaching a plateau as the end of the learning curve.
Mathematically, to determine the exact point of transition we did the following:
Let B i be the i th biopsy performed. We defined T i as the time needed to perform biopsy B i . We defined D i as the percent difference in time of procedure between biopsy B i and biopsy B i+1 ,
We defined the transition point (i.e., end of learning curve) as the biopsy for which D i was less than 10% for more than 90% of the following biopsies.
We performed a separate analysis for transrectal and transperineal biopsies.
Outcome measurement (accuracy)
We used both graphical and mathematical analysis to determine the number of fusion biopsies that are needed to have consistent prostate cancer detection rates for PI-RADS 3 score.
Graphically, the predicted probability of prostate cancer diagnosis was plotted against the urologist experience for PI-RADS-3 score and represented separately for each biopsy approach.
Mathematically, to determine the exact point of transition we performed the following analysis for those patients with a PI-RADS 3 lesion.
Let B i be the i th biopsy performed. We define X i as the pathological result of biopsy B i ; X i ¼ 0; B i negative 1; B i positive . We define S i as the rate of positive pathologies out of i biopsies;
. The transition point (i.e., end of learning curve) was defined as the biopsy for which S i+1 − S i was less than 0.05 for all following biopsies. The clinical meaning of this mathematical model is that from this biopsy forward, the probability of cancer detection did not alter by more than 5%.
Results
Patients' characteristics are presented in Table 1 . Of the 779 patients, 523 patients underwent transrectal biopsy and 256 patients underwent transperineal biopsy. Median prostate volume was statistically larger among patients who underwent transperineal biopsies (43 cc vs. 56cc). A total of 68% of the cohort had undergone a previous biopsy of the prostate and 30% were on active surveillance and underwent a confirmatory biopsy.
Prostate cancer was detected among 385 patients (49%) ( Table 2 ). In patients who underwent transrectal biopsy prostate cancer detection rate was 36% for PI-RADS 3, 58% for PI-RADS 4, and 80% for PI-RADS 5. Significant prostate cancer was diagnosed in 22, 39, and 71% for PI-RADS 3, 4, and 5, respectively. In patients who underwent transperineal biopsy prostate cancer detection rate was 44% for PI-RADS 3, 55% for PI-RADS 4, and 90% for PI- 
Process analysis
Mathematical analysis demonstrated the transition point for process (time of procedure in min) was 109 procedures for transrectal and 124 procedures for transperineal. Procedure time decreased from 45 min in the first transrectal fusion biopsies to 15 min after 109 biopsies and remained stable (p < 0.0001) ( Fig.1) . For transperineal fusion biopsy procedure time decreased from 55 min in the first transrectal fusion biopsies to 18 min after 124 biopsies and remained stable (p < 0.0001) ( Fig. 1 ).
Outcome analysis
Since prostate cancer detection rate significantly differs between PI-RADS 3,4, and 5 lesions, the analysis of the outcome learning curve is stratified by PI-RADS [10, 11] .
Mathematical analysis demonstrated the transition point for outcome measurement (rate of cancer detection for PI-RADS 3 lesions) was 104 for transrectal and 119 for transperineal.
In transrectal fusion biopsies we observed an increment in detection rate for PI-RADS 3 lesions from 35 to 50% after 110 biopsies and reaching a plateau afterwards ( Fig. 2a) .
In transperineal fusion biopsies we observed an increment in detection rate for PI-RADS 3 lesions from 30 to 55% reaching a plateau after 130 biopsies (Fig. 2b) .
According to the results of the PI-RADS 3 analysis, the number of patients with PI-RADS 4 or with PI-RADS 5 ( Table 2) would not permit a robust model, and therefore were not analyzed. 
Discussion
We aimed to define the learning curve of MP-MRI-targeted biopsy both in the transrectal and transperineal approach. We assessed the learning curve in two aspects: process (time of procedure) and outcome (accuracy rate). We demonstrated that proficiency (process + outcome) occurs after 110 transrectal and 125 transperineal fusion biopsies.
Limited data exist regarding the learning curve of MP-MRI-targeted biopsy. Most previous reports focused on outcome measures. Gaziev et al. demonstrated an increase of 36% in prostate cancer detection between the first and last 70 patients undergoing with MP-MRI-targeted transperineal biopsies [12] . Meng et al. focused on men undergoing repeated fusion biopsies and demonstrated a 26% rise over time in diagnosis of clinically significant prostate cancer [13] . Calio et al. reported the learning curve of MRI-TRUS fusion biopsy in a cohort of patients segmented into three groups. In the early group, fusion and systematic biopsy had comparable clinically significant cancer detection rates. However, in the second and third groups, fusion biopsy detected more clinically significant disease compared to systematic biopsy [14] .
Choosing the correct variable to measure surgical learning curve is essential. There are two main types of variables: surgical process and patient outcomes [15, 16] . The outcome of fusion biopsies is cancer detection rate. This is dependent on many factors including: correct performance and interpretation of MP-MRI by the radiologists, software co-registration, and the urologist performing the biopsy [17, 18] . It is very hard to disentangle the improvement over time of all these factors. Therefore any study focusing only on the outcome can misinterpret the relative contribution of surgical expertise.
To overcome this bias we decided to measure process as well as outcome. One of the most common variables used to measure process is surgical time [15] . In our analysis the mathematical and graphical analysis both revealed a substantial role for surgeon experience. We demonstrated the first fusion biopsies took three times longer to complete than those performed after the learning period was completed. Another common variable to measure process is complication rates. Prostate biopsy complications include: infection, hematuria, and urinary retention [19, 20] . All these are largely patient related and to the best of our understanding not related to surgical expertise in performing biopsies.
Previous studies analyzed fusion biopsy learning curve by grouping consecutive cases into time associated blocks [13, 14] . Although this is a common method, splitting consecutive cases is arbitrary and may miss the exact transition point of expertise [15] . In our study we did not group patients but rather analyzed the learning curve considering all available data. Furthermore, in our study, the urologist performing the procedures had no previous experience in performing MP-MRI-targeted biopsy. Hence, our results may represent the true learning curve for a novice urologist performing this complex procedure.
Two different MRI-US fusion systems were used in this study for transperineal biopsy. Prostate cancer detection rate was recorded separately for each fusion system and no significant differences in prostate cancer detection rate were noted between them (date not shown).
The learning curve of two different biopsy approaches are reported in this study and the experience of one type of biopsy may have influenced the other. The physician performing the targeted biopsies started his learning curve in the transrectal approach and after 6 months the transperineal was performed and learned independently throughout the rest of the study period.
This study has several key strengths including its large sample size and pragmatism. We did not limit the performance of MP-MRI to academic centers. Moreover, either 1.5-T with endorectal coil or 3.0-T MRI machines were allowed to take part. Also, two fusion software were used and either transperineal or transrectal access was permitted. Although a radiologist interpreted the MRI images, the urologist did the registration, and segmentation.
This current study has limitations. First, this is a singlesurgeon study and our results may not be representative of other operators. However, the methodology we used may be applied by other physicians to determine their own learning Fig. 2 The outcome learning curve for MRI-US fusion biopsy. Prostate cancer detection rate per 10 MRI-US fusion biopsies plotted agains increasing urologist experience for PI-RADS 3 lesions (a) transrectal approach (b) transperineal approach. To graphically demonstrate the learning curve a best fit biphasic polynomial line was plotted. Pca prostate cancer, TR transrectal, TP transperineal curve. Several potentially unknown selection biases may influence the surgeon choice of approach over time leading to differences in outcomes. However, the focus of our study was the learning curve and not the pathology outcome. The numbers for PI-RADS 4 and 5 were too small to draw conclusion. Hence, we did not calculate the outcome learning curve of these lesions. However, there is no reason to believe that the learning curve would be difference for PI-RADS 3, 4, and 5 lesions. As they all involve the correct MRI interpretation, proper targeting, and biopsy.
In conclusion, our study presents the first prospectively collected outcomes data for a single surgeon performing MP-MRI-targeted biopsy both in the transrectal and the transperineal approach. We demonstrated that fusion biopsies do require expertise. We calculated that the transition point is achieved after 110-125 cases. Improvement was evident both in reducing time of procedure and in improving cancer detection rates.
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